1455093-98-7

Upstream product

• 64169-34-2 5-bromophthalide 
• 100-39-0 benzyl bromide 

Downstream Products

• 1455094-02-6 methyl 4-hydroxy-7-(4-methoxybenzylamino)isoquinoline-3-carboxylate 
• 1455089-60-7 5-{[4-hydroxy-7-(4-methoxybenzylamino)isoquinoline-3-carbonyl]amino}pentanoic acid 
• 1455094-05-9 methyl 3-(4-hydroxy-7-(4-methoxybenzylamino)isoquinoline-3-carboxamido)-2,2-dimethylpropanoate 
• 1455089-62-9 3-(4-hydroxy-7-(4-methoxybenzylamino)isoquinoline-3-carboxamido)-2,2-dimethylpropanoic acid 
• 1455090-07-9 3-[(7-benzyl-4-hydroxyisoquinoline-3-carbonyl)amino]-2,2-dimethylpropionic acid 
• 1455094-00-4 methyl 4-(benzyloxy)-7-(4-methoxybenzylamino)isoquinoline-3-carboxylate 
• 945740-92-1 7-benzyl-4-hydroxyisoquinoline-3-carboxylic acid methyl ester 
• 945739-84-4 2-(7-benzyl-1-cyano-4-hydroxyisoquinoline-3-carboxamido)acetic acid 

Relevant academic research and scientific papers

Isoquinolone compound and application thereof

The invention relates to an isoquinolone compound and application thereof. The invention in particular relates to an isoquinolone compound used as a HIF prolyl hydroxylase inhibitor (HIF-PHI) and a pharmaceutical composition thereof. Moreover, the present invention provides the application of the isoquinolinone compound or the pharmaceutical composition thereof in the preparation of a medicament for preventing or treating HIF-associated or HIF-mediated diseases as anemia or ischemia, local ischemia or hypoxia.

4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS

The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.